MoonLake Immunotherapeutics (MLTX) - Dilution Analysis

10-Q filing | 71.3M shares outstanding

8-K filing: MoonLake Immunotherapeutics entered into an underwriting agreement to issue and sell 7,142,857 Class A ordinary shares at $10.50 per share, with gross proceeds expected to be $75 million. ($75.0M proceeds)

10-Q filing | 63.4M shares outstanding

10-Q filing | 63.3M shares outstanding

10-Q filing | 63.2M shares outstanding

10-K filing | 62.9M shares outstanding

10-Q filing | 62.9M shares outstanding

10-Q filing | 62.9M shares outstanding

10-Q filing | 62.6M shares outstanding

10-K filing | 62.9M shares outstanding

10-Q filing | 59.9M shares outstanding

S-3 filing: This S-3 filing from August 31, 2023, describes an at-the-market offering of Class A Ordinary Shares with an aggregate offering price of up to $350,000,000. The offering may be made from time to time through the sales agent, Leerink Partners, and the net proceeds will be used for working capital and general corporate purposes.

10-Q filing | 53.5M shares outstanding

8-K filing: MoonLake Immunotherapeutics closed an offering of 8,000,000 Class A ordinary shares at $50.00 per share, with an additional 1,200,000 shares sold through the exercise of an underwriter option, resulting in gross proceeds of $460 million. ($460.0M proceeds)

10-Q filing | 43.7M shares outstanding

POS AM filing: This is a POS AM filing for MoonLake Immunotherapeutics regarding the offering of Class A Ordinary Shares by Selling Shareholders.

S-3 filing: This is an S-3 filing for a shelf offering of securities, potentially including common stock, preferred stock, or debt securities. The specific terms of the securities will be determined at the time of issuance.

10-K filing | 39.2M shares outstanding

POS AM filing: This is a POS AM filing registering the offer and sale of Class A Ordinary Shares by Selling Shareholders, including shares issuable upon the exchange of MoonLake AG Common Shares and surrender of Class C Ordinary Shares.

10-Q filing | 36.9M shares outstanding

10-Q filing | 35.2M shares outstanding

S-1/A filing: The filing relates to the offer and sale from time to time by the Selling Shareholders of up to 49,281,756 Class A Ordinary Shares.

S-1/A filing: This S-1/A filing reflects the issuance of Class A and Class C Ordinary Shares, conversion of Class B to Class A Ordinary Shares, and includes details about a private placement (PIPE) and shares offered by selling shareholders.

10-Q filing | 36.9M shares outstanding

S-1/A filing: This S-1/A filing from MoonLake Immunotherapeutics details the offering of Helix Class A Ordinary Shares and includes information about the company's financial condition, business operations, and risk factors.

S-1/A filing: This S-1/A filing registers the resale of up to 11,500,000 Class A Ordinary Shares of Helix Acquisition Corp. by the selling shareholders, expected to be issued in private placements prior to the business combination with MoonLake Immunotherapeutics AG.

S-1/A filing: This S-1/A filing from Helix Acquisition Corp. details an offering of up to 11,500,000 Class A Ordinary Shares by selling shareholders, expected to be issued immediately prior to the consummation of the Business Combination pursuant to the terms of the Subscription Agreements, as well as 430,000 private placement shares at a price of $10.00 per share.

10-K filing | 11.9M shares outstanding

S-1 filing: This S-1 filing by Helix Acquisition Corp. relates to the offering of up to 11,500,000 Class A Ordinary Shares by selling shareholders, expected to be issued immediately prior to the consummation of the Business Combination, as well as the 430,000 Class A Ordinary Shares purchased by the Sponsor.

10-Q filing | 11.9M shares outstanding

8-K filing: Helix Acquisition Corp. entered into a Business Combination Agreement with MoonLake Immunotherapeutics AG, where Helix will acquire a controlling equity interest in MoonLake in exchange for a cash contribution, and existing MoonLake equity holders will retain their equity and receive non-economic voting shares in Helix. ($115.0M proceeds)

10-Q filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

10-K filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

8-K filing: Helix Acquisition Corp. consummated its initial public offering of 11,500,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $115,000,000, and completed a private sale of 430,000 Class A Ordinary Shares to Helix Holdings LLC at $10.00 per share, generating gross proceeds of $4,300,000. ($119.3M proceeds)

8-K filing: Helix Acquisition Corp. consummated its initial public offering of 11,500,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $115,000,000, and also completed a private sale of 430,000 Class A Ordinary Shares to the Sponsor at $10.00 per share, generating gross proceeds of $4,300,000. ($119.3M proceeds)

S-1/A filing: The sponsor has committed to purchase 400,000 private placement shares at a price of $10.00 per share, for an aggregate of $4,000,000 in a private placement that will close simultaneously with the closing of this offering.

S-1/A filing: This is an S-1/A filing related to a business combination. It details the definitions of various terms used in the document, including Business Combination, Ordinary Shares, Founder Shares, Initial Shareholders, Private Placement Shares, Shares, Public Shareholders, Trust Account, and Transfer.

S-1 filing: This is an initial public offering of Class A ordinary shares of Helix Acquisition Corp., a blank check company, with an offering size of $100,000,000 at $10.00 per share.